Recently, it has been demonstrated that CHD5 promoter hypermethylation results in low or absent CHD5 protein levels in lung cancer [21] and that elevated JMJD2A expression observed in lung tumors of both human and mouse could contribute to the reduction of CHD5 levels [31]. This evidence concerns the gene CHD5 and lung carcinoma.